Aileron Therapeutics Reports Second Quarter 2017 Financial Results
Initial clinical data showing anti-tumor activity with ALRN-6924 presented at ASCO 2017 -Presentation selected for Best of ASCO Meetings Ongoing enrollment of clinical trials in PTCL and AML/MDS Initial public offering raised $50 million in net proceeds …